Stryker Corporation

New York Stock Exchange
Back to all articles
Somewhat Bullish +50

Analysts Offer Insights on Healthcare Companies: Stryker (SYK) and Establishment Labs Holdings (ESTA)

📈 Analyst Rick Wise at Stifel Nicolaus maintained a Buy rating on Stryker (SYK) with a price target of $360.00, despite his personal track record showing a -2.2% average return and 43.8% success rate.

🏥 The healthcare sector is viewed as optimistic, supported by consensus ratings that show Strong Buy status for both Stryker and Establishment Labs Holdings (ESTA).

📊 Stryker currently has an analyst consensus price target of $401.19, representing a 28.0% upside from its closing price of $294.73.

🤖 TipRanks – DeepSeek upgraded Stryker to a Buy rating with a price target of $326.00 in a recent report.

🔬 Establishment Labs Holdings (ESTA) received a reiterated Buy rating from TD Cowen analyst Josh Jennings, who set a price target of $95.00 on shares closing at $70.23.

⭐ Analyst Josh Jennings at TD Cowen holds a 2-star rating with a 42.9% success rate and covers the Healthcare sector including Baxter International and Edwards Lifesciences.

📉 Recent analyst actions show mixed sentiment for Stryker, with Goldman Sachs raising its target to $361 while others like Baird, Bernstein, Evercore ISI, and JPMorgan lowered theirs.

🔍 Establishment Labs Holdings maintains a consensus price target of $87.71, which offers a 29.5% upside from current market levels.

🛡 Canaccord Genuity maintained a Buy rating on Establishment Labs Holdings with a $90.00 price target in a report issued on April 24.

⚠️ The article includes a disclaimer noting that the content is third-party material that the Globe and Mail has not reviewed or endorsed.

💰 Readers are encouraged to unlock hedge fund-level data via TipRanks for smarter investing decisions regarding these healthcare stocks.

📜 This content is syndicated, and the publisher may receive compensation for the placement of this article on their site.

Bullish Signals
  • Stryker (SYK) maintains a Strong Buy analyst consensus with a price target of $401.19, indicating significant upside potential.
  • Stifel Nicolaus analyst Rick Wise reiterated a Buy rating on Stryker with a $360.00 price target, while the current trading price is $294.73.
  • TipRanks – DeepSeek upgraded Stryker to a Buy rating and set a $326.00 price target.
  • Establishment Labs Holdings (ESTA) holds a Strong Buy analyst consensus with an average price target of $87.71, reflecting a 29.5% upside from current levels.
  • TD Cowen analyst Josh Jennings reiterated a Buy rating on Establishment Labs Holdings with a $90.00 price target.
  • Canaccord Genuity maintained a Buy rating on Establishment Labs Holdings with a $90.00 price target.
Risk Factors
  • Despite the bullish consensus, several major banks lowered their Stryker (SYK) price targets recently: Goldman Sachs cut it to $361 from $357 (though the text says raised, context implies mixed signals), Baird lowered to $385 from $437, Bernstein to $410 from $465, Evercore ISI to $355 from $365, and JPMorgan to $400 from $445.
  • Analyst Rick Wise of Stifel Nicolaus has a poor track record with an average return of -2.2% and a 43.8% success rate, suggesting limited reliability for his bullish $360 price target.
  • While the aggregate analyst consensus shows significant upside (28.0% for SYK), individual institutional investors are increasingly cautious, evidenced by multiple downgrades on price targets during the recent period.
  • The article is heavily promotional content that has not been reviewed or endorsed by Globe and Mail, containing paid placements which may introduce bias.
Full Analysis
Stifel Nicolaus analyst Rick Wise initiated coverage for Stryker with a Buy rating and set a price target of $360, noting the company's current share price closed at $294.73. The analysis highlights that Stryker currently holds a Strong Buy consensus among analysts with an average price target of $401.19, representing approximately 28% upside from recent trading levels. Additionally, TipRanks identified DeepSeek as upgrading the stock to Buy with a lower price target of $326. Conversely, Establishment Labs Holdings received a reiterated Buy rating from TD Cowen analyst Josh Jennings who set a price target at $95 against a share price closing near $70.23. The consensus for Establishment Labs is a Strong Buy with an average price target of $87.71, indicating roughly 29.5% upside. This positive sentiment was supported by Canaccord Genuity, which maintained a Buy rating on April 24 with a $90 target. Beyond these specific upgrades, the broader analyst landscape for Stryker presents a mixed picture of recent adjustments. Goldman Sachs raised its price target to $361, suggesting confidence in near-term valuation. However, several other major firms have recently lowered their targets: Baird cut its target from $437 to $385, Bernstein reduced it from $465 to $410, Evercore ISI lowered it from $445 to $400, and JPMorgan decreased its target from $445 to $400.